Navigation Links
Signum Dermalogix Receives $1.6M Phase II SBIR Grant for the Development of Novel Atopic Dermatitis Therapeutics
Date:11/14/2013

PRINCETON, N.J., Nov. 14, 2013 /PRNewswire/ -- Signum Dermalogix, Inc. ("Dermalogix") announced today that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the company a Small Business Innovation Research (SBIR) Phase II grant totaling $1.6 million for the development of a topical drug candidate for atopic dermatitis.  

Utilizing the funding provided with the earlier Phase I grant, Dermalogix established a novel screening paradigm to effectively identify potent therapeutic compounds from its isoprenylcysteine (IPC) technology platform. These screening efforts resulted in the identification of several IPC compounds possessing anti-inflammatory and anti-microbial activity. This Phase II funding will be used to select a lead drug candidate and commence IND-enabling safety/toxicology studies.

"This award is further validation of the potential for IPC compounds in dermatology. We are pleased to be awarded this grant by the NIH and our objective continues to be the development of our technology with the goal of delivering therapeutic agents to treat skin disease," stated Maxwell Stock, President & CEO.

Dermalogix has a successful track record in receiving and executing on NIH funding. Recently, with National Institute of Allergy and Infectious Diseases (NIAID) SBIR funding, Dermalogix announced that an Investigational New Drug (IND) Application to evaluate IPC compound SIG990 in rosacea has been cleared by the FDA. Dr. Eduardo Perez, VP of R&D and Business Development stated, "Building on the experience and momentum provided by SIG990, we believe successful development of our novel class of topical IPC compounds will provide an important additional, and potentially better, therapeutic option for people suffering atopic dermatitis."  

About Signum Dermalogix
Signum Dermalogix is a dermatological focused company, developing novel cosmetic ingredients and drug compounds. Dermalogix also provides dermatology testing, custom assay development and analytical services. For more information please visit: www.signumdermalogix.com


'/>"/>
SOURCE Signum Dermalogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
2. IntelligentMDx Receives FDA Clearance for IMDx C. difficile for Abbott m2000 Assay, Completes Move of Corporate Headquarters to Waltham
3. Numotion Receives 2013 MDA Company of the Year Award
4. EndoShape Receives 510(k) Clearance for Polymer Embolization Device
5. Actinobac Biomed Founder Receives Two Awards For Promising New Drug
6. ARMGO Pharma Receives Research Grant Award from Kennedys Disease Association to Support Advancement of Rycal Compounds
7. Seventh Sense Biosystems Receives CE Mark Approval for its Touch Activated Phlebotomy Blood Collection and Testing System
8. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
9. ARRAYit Corporation Receives Purchase Order from ChemBio
10. IGI Laboratories, Inc. Receives Formal US FDA Approval For Site Transfer Of Econazole Nitrate
11. Par Pharmaceuticals Karen OConnor Receives 2013 Cardinal Health Supply Chain Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... innovative, personalized cell-based treatment for a high-risk form of the most common ... Hospital of Philadelphia today reported new results using ... The physician-scientists presented findings at the annual meeting of the American ... Continue Reading ... ...
(Date:12/2/2016)... , Dec 2, 2016 Research and Markets ... newsletter to their offering. ... , , R&D Drug ... Publishing,s proprietary R&D Drug Pipeline Database provides 24/7 online access to ... on the market and on investigational drug candidates in research & ...
(Date:12/2/2016)... Columbia , December 2, 2016 - bioLytical lanza el ... nuevas directrices de la OMS     Continue Reading ... ... , , ... enfermedades infecciosas, ha anunciado hoy que está expandiendo el lanzamiento de su INSTI ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi and ... who do not do their research and undergo cosmetic dermatology treatments from unqualified practitioners ... of a renaissance and every other month a new treatment or device is launched, ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... called the CardioQuick Patch® significantly improves the reproducibility and accuracy of placing precordial ... healthcare settings. , Over the last 60 years, studies have shown that ...
(Date:12/4/2016)... ... 03, 2016 , ... While James Earl Jones is known for myriad roles ... show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a very ... in large part due to early detection. Like any other disease, treatments have a ...
(Date:12/4/2016)... CA (PRWEB) , ... December 04, 2016 , ... ... without undergoing major cosmetic surgery can now take advantage of a cosmetic procedure ... advanced skin rejuvenation treatment that reduces the appearance of age spots, fine ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in ... Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New ... Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and ...
Breaking Medicine News(10 mins):